NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 12, 2023 and accepted by EDGAR at May 12, 2023, 20:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $466.2k | us-gaap:Revenues |
| Revenue | 6 months2022-10-01 to 2023-03-31 | $580.8k | us-gaap:Revenues |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $434.7k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-10-01 to 2023-03-31 | $561.6k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $31.5k | us-gaap:GrossProfit |
| Gross profit | 6 months2022-10-01 to 2023-03-31 | $19.2k | us-gaap:GrossProfit |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $1.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-10-01 to 2023-03-31 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $1.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-10-01 to 2023-03-31 | $3.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$3.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-10-01 to 2023-03-31 | −$5.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$3.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-10-01 to 2023-03-31 | −$5.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-10-01 to 2023-03-31 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-10-01 to 2023-03-31 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 16,414,795 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-10-01 to 2023-03-31 | 16,321,891 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-10-01 to 2023-03-31 | −$7.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-10-01 to 2023-03-31 | $187.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $3.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $6.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $7.2m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $1.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $1.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $5.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-039030. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.